RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA
Clinical trials for RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA trials appear
Sign up with your email to follow new studies for RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail shows promise for hard-to-treat lymphoma
Disease control Recruiting nowThis study tests a combination of four drugs (zanubrutinib, rituximab, lenalidomide, and tislelizumab) in 33 adults with follicular lymphoma that has returned or not responded to at least two prior treatments. The goal is to see how well the combo shrinks or eliminates tumors aft…
Matched conditions: RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA
Phase: PHASE2 • Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Disease control
Last updated May 17, 2026 02:03 UTC
-
New hope for Tough-to-Treat lymphomas: experimental combo enters phase 3 trial
Disease control Recruiting nowThis study tests a new drug, odronextamab, combined with lenalidomide in people whose follicular or marginal zone lymphoma has returned or stopped responding to treatment. The trial compares this new combination to the current standard treatment (rituximab plus lenalidomide). Abo…
Matched conditions: RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA
Phase: PHASE3 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
New hope for lymphoma patients: drug combo trial launches
Disease control Recruiting nowThis study compares two drug combinations for people with follicular or marginal zone lymphoma that has come back or not responded to prior treatment. About 780 participants will receive either zanubrutinib plus an anti-CD20 antibody or lenalidomide plus rituximab. The goal is to…
Matched conditions: RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA
Phase: PHASE3 • Sponsor: BeiGene • Aim: Disease control
Last updated May 13, 2026 16:03 UTC
-
New hope for Tough-to-Treat lymphoma: mosunetuzumab under the microscope
Disease control Recruiting nowThis study looks back at medical records of 25 adults with relapsed or refractory follicular lymphoma who received mosunetuzumab through a compassionate use program after at least two prior therapies. The goal is to measure how many patients respond to the drug, how long they sta…
Matched conditions: RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA
Sponsor: Andrés José Maria Ferreri • Aim: Disease control
Last updated May 08, 2026 12:01 UTC